COVID-19 与多发性硬化症：两例阿仑单抗治疗病例描述。
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
机构信息
Neurology Department, Complejo Hospitalario Universitario de Albacete, Hermanos Falcó 37, Albacete, Castilla-La Mancha 02006, Spain.
Neurology Department, Complejo Hospitalario Universitario de Albacete, Hermanos Falcó 37, Albacete, Castilla-La Mancha 02006, Spain.
出版信息
Mult Scler Relat Disord. 2020 Oct;45:102402. doi: 10.1016/j.msard.2020.102402. Epub 2020 Jul 17.
BACKGROUND
Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice.
METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae.
CONCLUSION
In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.
背景
阿仑单抗是一种治疗多发性硬化症（MS）的药物。免疫抑制被认为是 SARS-CoV-2 感染的一个危险因素，目前仍缺乏指导 MS 实践的证据。
方法/结果：我们描述了两名正在接受阿仑单抗治疗的 MS 患者感染 COVID-19 的临床和免疫情况，其中一名患者在最后一次用药后仅一周就被感染，且两人均未留下后遗症而康复。
结论
在选择的患者（年轻、无合并症且疾病活动度高）中，MS 本身可能比 COVID-19 更危险，因此我们应考虑按原计划继续 MS 治疗，包括阿仑单抗。
Zotero 插件